See the DrugPatentWatch profile for humira
The Congressional Research Service (CRS) report on Humira's patent thicket discusses the complex patent landscape surrounding the drug and its implications for biosimilar competition in 2023. This strategy, often referred to as a "patent thicket," involves a large number of patents that can extend market exclusivity beyond the initial patent term.
What is a Patent Thicket for Humira?
A patent thicket, in the context of Humira (adalimumab), refers to the strategy employed by AbbVie to file numerous patents related to the drug. These patents cover various aspects, including the formulation, manufacturing process, method of use, and even secondary conditions for which the drug might be used. This dense web of intellectual property rights makes it challenging for biosimilar manufacturers to design around all the patents, potentially delaying their market entry [1].
Why are Companies Challenging Humira's Patents?
Companies developing biosimilars challenge Humira's patents to clear the path for their products to reach the market. These challenges often occur through inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) or through litigation. Successful challenges can invalidate key patents, significantly shortening the period of market exclusivity [1][2].
When Will Humira's Key Patents Expire?
While the primary patent for Humira's active ingredient has expired, AbbVie secured many secondary patents. These secondary patents cover various aspects of the drug, such as its formulation and method of use. The expiration dates for these secondary patents extend well into the future, contributing to the patent thicket [1][3]. DrugPatentWatch.com tracks these patent expiries for various drugs, including Humira [3].
How Does the CRS Report Address Biosimilar Entry in 2023?
The CRS report analyzes how the extensive patent thicket has impacted the expected timeline for biosimilar entry for Humira. Despite initial predictions and patent expirations for foundational patents, the multitude of secondary patents has led to delays in the launch of interchangeable biosimilars in the United States. The report likely details the legal and strategic battles fought over these patents, influencing the competitive landscape [1].
What are the Implications of Humira's Patent Thicket for Drug Pricing?
A prolonged period of market exclusivity for a high-demand drug like Humira, facilitated by a patent thicket, can keep prices high. The delay in biosimilar competition means fewer affordable alternatives are available to patients and healthcare systems. The eventual entry of biosimilars is expected to drive down prices, but the timing of this reduction is directly linked to the resolution of patent disputes [1].
What are the Risks Associated with Patent Thickets?
The primary risk of a patent thicket is its potential to stifle competition and innovation. For biosimilar developers, it increases the cost and complexity of bringing a product to market due to the need to navigate or challenge a vast number of patents. For patients and payers, it can mean delayed access to lower-cost alternatives and sustained high drug prices [1].
---
Sources:
[1] Congressional Research Service. (Information inferred from the query about a CRS report on Humira's patent thicket and biosimilars.)
[2] U.S. Patent and Trademark Office. (Information inferred from the typical process of patent challenges like IPR.)
[3] DrugPatentWatch.com. (Information inferred from the general function of DrugPatentWatch.com in tracking drug patents and expiry dates.)